Browse All

Current Filters

CLEAR FILTER x

TITLE

Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design

Author:Mystkowski, Paul   Johannsen, Peter   Bentsen, Marie   Attfield, Kate   FREDERIKSEN, Kristian   Frisoni, Giovanni   Jeppesen, Rose   Malik, Ibrahim   Knudsen, Lotte   

Session Name:P12: Aging, Dementia, and Behavioral Neurology: Alzheimer's Treatment  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:P12.017  

Author Institution:Novo Nordisk Inc., Plainsboro, NJ  Novo Nordisk A/S, Søborg, Denmark  John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom  Copenhagen University Hospital - Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Denmark  University of Geneva, Geneva, Switzerland  

Comparison of Eligibility Criteria and Baseline Characteristics Between the Patient Populations of evoke and evoke+, Clarity AD and TRAILBLAZER-ALZ-2

Author:Mystkowski, Paul   Feldman, Howard   Scheltens, Philip   Hansson, Oskar   Sano, Mary   van der Flier, Wiesje   Bardtrum, Lars   Johannsen, Peter   Jeppesen, Rose   Leon, Teresa   Hansen, Charlotte Thim   Cummings, Jeffrey   

Session Name:P12: Aging, Dementia, and Behavioral Neurology: Alzheimer's Treatment  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:P12.018  

Author Institution:Novo Nordisk Inc., Plainsboro, NJ  University of California San Diego, , La Jolla, CA  EQT Life Sciences Partners, Amsterdam, Netherlands  Lund University and Skåne University Hospital, Lund and Malmö, Sweden  Icahn School of Medicine at Mount Sinai and James J. Peters VAMC , Bronx, NY  Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands  Novo Nordisk A/S, Søborg, Denmark  University of Nevada, Las Vegas, NV